Table 1.
Characteristics of the study population .
| Clopidogrel (n=23) | Ticagrelor (n=23) | P-value | |
|---|---|---|---|
| Age, (years) | 67 ± 8 | 69 ± 9 | 0.4 |
| Male sex, no. (%) | 19 (83) | 20 (87) | 0.5 |
| BMI, (Kg/m 2 ) | 28 ± 5 | 28 ± 3 | 0.8 |
| Diabetes, no. (%) | 7 (30) | 8 (35) | 0.6 |
| Hypertension, no. (%) | 20 (87) | 18 (78) | 0.3 |
| Hyperlipidaemia, no. (%) | 17 (74) | 15 (65) | 0.4 |
| Current smoker, no. (%) | 6 (26) | 5 (22) | 0.4 |
| from years | 43 ± 10 | 42 ± 11 | 0.6 |
| Previous smoker, no. (%) | 17 (74) | 18 (78) | 0.4 |
| stopped from years | 10 ± 8 | 11 ± 9 | 0.7 |
| smoked for years | 31 ± 10 | 32 ± 13 | 0.8 |
| pack/years | 42 [26–50] | 40 [20–58] | 0.3 |
| Prior MI, no. (%) | 5 (22) | 4 (17) | 0.8 |
| Prior PCI, no. (%) | 6 (26) | 6 (26) | 0.9 |
| Prior CABG, no. (%) | 0 (0) | 0 (0) | 0.9 |
| Laboratory data at baseline | |||
| White blood cells, (U/µl) | 8 ± 1 | 8 ± 2 | 0.4 |
| Haemoglobin, (g/dl) | 13 ± 1 | 13 ± 1 | 0.6 |
| Platelets (U/µl) | 207 ± 64 | 204 ± 60 | 0.9 |
| Creatinine clearance, (ml/min) | 75 ± 8 | 70 ± 10 | 0.3 |
| LVEF (%) | 53 ± 8 | 54 ± 9 | 0.5 |
| COPD | |||
| Years from diagnosis, (years) | 11 ± 5 | 11 ± 6 | 0.9 |
| Mild AO no. (%) | 10 (43) | 11 (48) | 0.9 |
| Moderate AO no. (%) | 12 (52) | 11 (48) | 0.9 |
| Severe AO no. (%) | 1 (4) | 1 (4) | 0.9 |
| Very severe AO no. (%) | 0 (0) | 0 (0) | 0.9 |
| Cardiovascular therapy, no. (%) | |||
| Aspirin | 23 (100) | 23 (100) | 0.9 |
| Beta-blocker | 17 (74) | 17 (74) | 0.9 |
| ACE inhibitor/ARB | 21 (91) | 20 (87) | 0.9 |
| Statin | 23 (100) | 23 (100) | 0.9 |
| Calcium channel blockers | 8 (35) | 9 (39) | 0.7 |
| Nitrates | 3 (13) | 3 (13) | 0.9 |
| Proton pump inhibitor * | 8 (35) | 9 (39) | 0.7 |
| Respiratory therapy, no. (%) | |||
| Inhaled corticosteroids | 4 (17) | 5 (22) | 0.9 |
| Short-acting beta2 agonist | 8 (35) | 7 (30) | 0.9 |
| Long-acting beta2 agonist | 6 (26) | 8 (35) | 0.9 |
| Long-acting muscarinic antagonist | 9 (39) | 8 (35) | 0.9 |
BMI: body mass index. MI: myocardial infarction. PCI: percutaneous coronary intervention. CABG: coronary artery bypass graft. LVEF: left ventricle ejection fraction. COPD: chronic obstructive pulmonary disease. AO: airways obstruction. ACE: angiotensin converting enzyme. ARB: angiotensin II receptor blocker.
* pantoprazole was the only proton pump inhibitor administered.